Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study.
- Published in:
- Clinical Drug Investigation, 2016, v. 36, n. 3, p. 235, doi. 10.1007/s40261-015-0373-8
- By:
- Publication type:
- Article
Works matching IS 11732563 AND DT 2016 AND VI 36 AND IP 3
Results: 7
1
2
Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
- Published in:
- Clinical Drug Investigation, 2016, v. 36, n. 3, p. 195, doi. 10.1007/s40261-015-0366-7
- By:
- Publication type:
- Article
3
Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials.
- Published in:
- Clinical Drug Investigation, 2016, v. 36, n. 3, p. 177, doi. 10.1007/s40261-015-0361-z
- By:
- Publication type:
- Article
4
The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy.
- Published in:
- Clinical Drug Investigation, 2016, v. 36, n. 3, p. 203, doi. 10.1007/s40261-015-0367-6
- By:
- Publication type:
- Article
5
The Safety of Melatonin in Humans.
- Published in:
- Clinical Drug Investigation, 2016, v. 36, n. 3, p. 169, doi. 10.1007/s40261-015-0368-5
- By:
- Publication type:
- Article
6
Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain.
- Published in:
- Clinical Drug Investigation, 2016, v. 36, n. 3, p. 213, doi. 10.1007/s40261-015-0371-x
- By:
- Publication type:
- Article
7
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting.
- Published in:
- Clinical Drug Investigation, 2016, v. 36, n. 3, p. 225, doi. 10.1007/s40261-015-0372-9
- By:
- Publication type:
- Article